


## Thioperamide maleate

Cat. No.:	HY-12206A
CAS No.:	148440-81-7
Molecular Formula:	C <sub>15</sub> H <sub>24</sub> N <sub>4</sub> S.xC <sub>4</sub> H <sub>4</sub> O <sub>4</sub>
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 100 mg/mL (Need ultrasonic)
----------	--

### BIOLOGICAL ACTIVITY

Description	Thioperamide maleate (MR-12842 maleate) is a potent, orally available, brain penetrant and selective H3 receptor antagonist with a K <sub>i</sub> of 4.3 nM for inhibition of [ <sup>3</sup> H]histamine release. Thioperamide maleate inhibits [ <sup>3</sup> H]histamine synthesis with a K <sub>i</sub> of 31 nM <sup>[1]</sup> .								
IC <sub>50</sub> & Target	H <sub>3</sub> Receptor								
In Vitro	<p>Thioperamide inhibits [<sup>3</sup>H]-(R)-α-MeHA binding rat brain and guinea-pig lung with K<sub>i</sub>s of 2.1 nM and 2.0 nM, respectively. Thioperamide competitively blocks H3-autoreceptors regulating [<sup>3</sup>H]histamine release with a mean apparent K<sub>i</sub> of 4 nM<sup>[1]</sup>. Thioperamide (0.01-100 μM; 24 hours) promotes the viability of NE-4C stem cells in a concentration-dependent manner<sup>[2]</sup>. Thioperamide displays similar potencies at human H4 and H3 receptors (K<sub>i</sub>=43 and 60 nM, respectively)<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>NE-4C stem cells</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.1, 1, 10, 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>The viability of NE-4C stem cells increased significantly to 150.83±6.91% when (1 μM) was administrated, and increased to 145.11±14.52% and 132.02%±25.65% when 10 μM and 100 μM were administrated respectively.</td> </tr> </table>	Cell Line:	NE-4C stem cells	Concentration:	0.01, 0.1, 1, 10, 100 μM	Incubation Time:	24 hours	Result:	The viability of NE-4C stem cells increased significantly to 150.83±6.91% when (1 μM) was administrated, and increased to 145.11±14.52% and 132.02%±25.65% when 10 μM and 100 μM were administrated respectively.
Cell Line:	NE-4C stem cells								
Concentration:	0.01, 0.1, 1, 10, 100 μM								
Incubation Time:	24 hours								
Result:	The viability of NE-4C stem cells increased significantly to 150.83±6.91% when (1 μM) was administrated, and increased to 145.11±14.52% and 132.02%±25.65% when 10 μM and 100 μM were administrated respectively.								
In Vivo	<p>Thioperamide (5-20 mg/kg; i.p.) is able to facilitate reconsolidation of a contextually-conditioned fear memory in C57BL/6J mice<sup>[4]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

Animal Model:	Naive female C57BL/6J mice <sup>[4]</sup>
Dosage:	5, 10 or 20 mg/kg
Administration:	Injections (i.p.)
Result:	Facilitated reconsolidation of a contextually-conditioned fear memory.

## REFERENCES

- [1]. J M Arrang, et al. Highly Potent and Selective Ligands for Histamine H<sub>3</sub>-receptors. *Nature*. 1987 May 14-20;327(6118):117-23.
- [2]. Na Wang, et al. Histamine H<sub>3</sub> Receptor Antagonist Enhances Neurogenesis and Improves Chronic Cerebral Hypoperfusion-Induced Cognitive Impairments. *Front Pharmacol*. 2020 Jan 21;10:1583.
- [3]. Y Charlier, et al. Differential Effects of Histamine H<sub>3</sub> Receptor Inverse Agonist Thioperamide, Given Alone or in Combination With the N-methyl-d-aspartate Receptor Antagonist Dizocilpine, on Reconsolidation and Consolidation of a Contextual Fear Memory in Mice. *Neuroscience*. 2011 Oct 13;193:132-42.
- [4]. Gbahou F, et al. Compared pharmacology of human histamine H<sub>3</sub> and H<sub>4</sub> receptors: structure-activity relationships of histamine derivatives. *Br J Pharmacol*. 2006;147(7):744-754.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA